Screener
Acadia Pharmaceuticals ACAD Other Non-Current Assets
Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Restricted cash | 7,846 | 7,845 |
| Long-term inventory | 76,301 | 76,704 |
| Deferred tax assets | 240,679 | 249,879 |
| Other assets | 3,550 | 3,896 |
| Total assets | $1,742,900 | $1,564,195 |
| Liabilities and stockholders’ equity | ||
| Accounts payable | $44,566 | $10,903 |
| Accrued liabilities | 316,870 | 266,211 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Acadia Pharmaceuticals's other non-current assets?
- Acadia Pharmaceuticals (ACAD) reported other non-current assets of $3.55M in Q2 2026.
- How has Acadia Pharmaceuticals's other non-current assets changed year-over-year?
- Acadia Pharmaceuticals's other non-current assets increased by 57.6% year-over-year, from $2.25M to $3.55M.
- What is the long-term trend for Acadia Pharmaceuticals's other non-current assets?
- Over 5 years (2020 to 2025), Acadia Pharmaceuticals's other non-current assets has grown at a 18.3% compound annual growth rate (CAGR), from $1.68M to $3.9M.
- What does other non-current assets mean?
- Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.
Ask your AI about Acadia Pharmaceuticals's other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude